Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T20:03:43.868Z.
Calculation as of: 2026-10-06T20:03:43.868Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: be51af8dbdcf828107064bcf61af75d59853c311cbc38d104ed49a07c9c6f929
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$1.22B
EBITDA Yield
6.97%
TTM Avg
3.73%
3Y Avg
2.86%
5Y Avg
4.37%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ORIC Pharmaceuticals, Inc. (ORIC) | $1.24B | N/A | N/A | N/A | N/A |
| Omada Health (OMDA)vs › | $1.23B | 0.69% | 0.59% | 0.59% | 0.59% |
| Cronos Group Inc. (CRON)vs › | $1.23B | 3.56% | 5.34% | 5.34% | 5.34% |
| Innovage Holding Corp. (INNV)vs › | $1.22B | 6.97% | 3.73% | 2.86% | 4.37% |
| Tyra Biosciences, Inc. (TYRA)vs › | $1.21B | N/A | N/A | N/A | N/A |
| Kardigan, Inc. (KARD)vs › | $1.21B | N/A | N/A | N/A | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.20B | N/A | N/A | N/A | N/A |
| MannKind Corporation (MNKD)vs › | $1.18B | 1.95% | 3.43% | 3.63% | 3.63% |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.31B | N/A | N/A | N/A | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.33B | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
